Search Results
Your search for Fred R. Hirsch, MD, PhD,Fred R. Hirsch, MD, PhD matches 27 pages
Showing 1 - 27IASLC Presents WCLC 2021 Lectureship Awards to International Array of Lung Cancer Researchers
The International association for the Study of Lung Cancer (IASLC), at its 2021 World Conference on Lung Cancer (WCLC), presented awards to clinicians and researchers who made significant contributions to the treatment of patients with lung cancer. The awards represent many major categories of lung ...
National Cancer Act and Lung Cancer Screening: An Example of Intended Impact
The National Cancer Act of 1971 established a national priority to address the widely shared dread of a cancer diagnosis. The goal of the National Cancer Act was to strengthen the National Cancer Institute (NCI) to more effectively carry out the national effort against cancer. After the Act was...
ASCO Honors 2021 Special Awards Recipients
Researchers, patient advocates, and global oncology leaders who have worked to reshape cancer care around the world are among the recipients of ASCO’s Special Awards—the Society’s highest honors—and the Women Who Conquer Cancer Mentorship Awards from Conquer Cancer, the ASCO Foundation. “The...
Fred R. Hirsch, MD, PhD, on Searching for Therapeutic Strategies for Patients With Lung Cancer and COVID-19 Infection
Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, invites his colleagues to enroll their patients in a large prospective study, for which he serves as Principal Investigator. The study is searching for solutions for treating patients with lung cancer who also have the coronavirus, because so...
Fred R. Hirsch, MD, PhD, on Lung Cancer: Survival and Tumor Mutation Burden
Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked to overall and progression-free survival across two immunotherapy trials, and was independent of PD-L1 status (Abstract...
CURE Media Group Announces Recipients of 2020 Lung Cancer Heroes Award
The CURE Media Group, a multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, recently announced four recipients of the inaugural 2020 Lung Cancer Heroes awards and the recipient of the Lifetime Achievement award. The 2020 Lung Cancer Heroes are:...
Fred R. Hirsch, MD, PhD, on Early-Stage Lung Cancer: Targeted Treatment and Screening
Fred R. Hirsch, MD, PhD, of The Tisch Cancer Institute at Mount Sinai, discusses lung cancer screening for aggressive early-stage lung cancer; adjuvant and neoadjuvant treatment, including the ADAURA study of EGFR-positive tumors; and how cell-free DNA analysis might be used in the future to...
How the Lung Cancer Community Came Together During the COVID-19 Pandemic
The COVID-19 pandemic (caused by infection with the SARS-CoV-2 coronavirus) has created a host of diagnostic, treatment, and follow-up problems for patients with cancer of all types, and this is particularly true for patients with lung cancer, their families, and providers. Everyone wanted to...
International Association for the Study of Lung Cancer Names Research Award After Fred R. Hirsch, MD, PhD
The International Association for the Study of Lung Cancer (IASLC) recently announced it is naming the Translational Research Lectureship Award after longtime member and former IASLC Chief Executive Officer Fred R. Hirsch, MD, PhD. The award, which was previously named after Adi Gazdar, MD, who...
Fred R. Hirsch, MD, PhD, Named Executive Director of New Center for Thoracic Oncology at Mount Sinai
Fred R. Hirsch, MD, PhD, an authority on lung cancer treatment and research, has joined Mount Sinai Health System as Executive Director of the newly created Center for Thoracic Oncology in The Tisch Cancer Institute at Mount Sinai and will also serve as the Richard M. Stein, MD, Joe Lowe, and...
Progress With ALK Inhibitors: When Will We Consider ALK-Positive Lung Cancer a ‘Chronic Disease’?
As reported by Solomon et al in The Lancet Oncology1 and reviewed in this issue of The ASCO Post, results from a global phase II study of the third-generation ALK inhibitor lorlatinib showed a high overall response rate and high intracranial response rate for patients with advanced ALK-positive...
IASLC Announces Dave Mesko, MBA, as New Chief Executive
THE INTERNATIONAL Association for the Study of Lung Cancer (IASLC) has announced Dave Mesko, MBA, as its new Chief Executive Officer. Mr. Mesko replaces Fred R. Hirsch, MD, PhD, who left IASLC after his 5-year term ended on October 31, 2018. Mr. Mesko will be primarily responsible for the overall ...
Françoise Mornex, MD, PhD, Honored With IASLC Distinguished Award
Françoise Mornex, MD, PhD, was recognized by the International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada. Dr. Mornex is Professor of Oncology at the University Claude Bernard in Lyon,...
Fadlo R. Khuri, MD, FACP, Acknowledged With IASLC Lifetime Scientific Achievement Award
Oncologist, physician, and Professor, Fadlo R. Khuri, MD, FACP, has been recognized by the International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto. Dr. Khuri received the Joseph W. Cullen...
Eva Koziolek, DSc, PhD, Awarded First Free Me From Lung Cancer–IASLC Joint Fellowship Award
FREE ME FROM LUNG CANCER (FMFLC) and the International Association for the Study of Lung Cancer (IASLC) have announced the first-ever winner of the FMFLC-IASLC Foundation Joint Fellowship Award for the Early Detection of Lung Cancer. The FMFLC-IASLC Joint Fellowship Award supports novel,...
Charles Swanton, PhD, FRCP, Receives IASLC Paul A. Bunn, Jr, Scientific Award
CHARLES SWANTON, PhD, FRCP, of The Francis Crick Institute, London, was recognized by the International Association for the Study of Lung Cancer (IASLC) at the 2018 IASLC World Conference on Lung Cancer with the Paul A. Bunn, Jr, Scientific Award, honoring his lifetime achievements in scientific...
IASLC Issues Statement Paper on Liquid Biopsy for Lung Cancer
The lungs can be a difficult organ to biopsy with a needle, so the promise of identifying lung cancer through a blood-based biopsy has lung cancer experts and patients optimistic. Knowing how and when to use a liquid biopsy is critically important and led global experts at the International...
Cancer Collaboration Launches New Lung Cancer Patient Registry
The Bonnie J. Addario Lung Cancer Foundation and the American Lung Association’s LUNG FORCE welcome the International Association for the Study of Lung Cancer as a new member of the Lung Cancer Patient Registry, a place to gather and store detailed patient information, providing a real-world view...
Roy S. Herbst, MD, PhD, Receives 2016 Paul A. Bunn Jr. Scientific Award
Roy S. Herbst, MD, PhD, of Yale University, New Haven, Connecticut, was recognized by the International Association for the Study of Lung Cancer (IASLC) with a distinguished award at the 17th World Conference on Lung Cancer in Vienna, Austria. Dr. Herbst accepted the Paul A. Bunn Jr. Scientific...
Fred R. Hirsch, MD, PhD, and Paul A. Bunn, Jr., MD, on the Highlights of the World Conference on Lung Cancer
Fred R. Hirsch, MD, PhD, of the University of Colorado Health Science Center, and Paul A. Bunn, Jr, MD, of the University of Colorado Cancer Center, give their views on the goals and important presentations of the 2015 World Conference on Lung Cancer.
Tony Mok, MD, and Fred R. Hirsch, MD, PhD: Summary of the IASLC Presidential Symposium
Tony Mok, MD, of The Chinese University of Hong Kong, and Fred R. Hirsch, MD, PhD, of University of Colorado Health Science Center discuss the highlights of the featured plenary session, which included the conference’s top four abstracts (Abstract PLEN04).
The Tissue Is the Issue: Choosing Therapy for Lung Cancer
The new guidelines from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology (CAP/IASLC/AMP) are a significant step toward personalized therapy of patients with lung cancer. More than 226,000 new patients per year are...
Where Are We With ALK Inhibition in Lung Cancer?
The prospective phase III PROFILE 1007 study compared the ALK inhibitor crizotinib (Xalkori) to chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) with ALK gene–rearranged tumors refractory to previous chemotherapy. The study showed a clear superiority for crizotinib in terms ...
ASCO Endorses CAP/IASLC/AMP Guidelines for Molecular Testing of Patients With Non–Small Cell Lung Cancer
Personalized medicine is an established treatment concept for patients with advanced non–small cell lung cancer (NSCLC), and molecular characterization of tumors is crucial for choice of (first-line) therapy. As of right now, we have U.S. Food and Drug Administration (FDA)-approved drugs for two...
Fred R. Hirsch, MD, PhD, Presented With 2015 Addario Lectureship Award
The Bonnie J. Addario Lung Cancer Foundation (ALCF) honored Fred R. Hirsch, MD, PhD, with the 2015 Addario Lectureship Award for his continued leadership and expertise in lung cancer treatment and research. Dr. Hirsch, CEO of the International Association for the Study of Lung Cancer (IASLC),...
EGFR Gene Copy Number as Biomarker for Antibody Treatment in Squamous Cell NSCLC
Two studies presented at the 16th World Conference on Lung Cancer suggest that high expression of the epidermal growth factor receptor (EGFR), or gene copy number, may indicate potential benefit from EGFR antibodies in squamous cell non–small cell lung cancer (NSCLC). The studies were presented by...
WCLC: Effect of EGFR Protein and EGFR Gene Copy Number in SQUIRE Trial
Previously, researchers reporting on the SQUIRE study demonstrated that the addition of necitumumab to gemcitabine-cisplatin improved overall survival in patients with stage IV squamous non–small cell lung cancer (NSCLC). Following up on these findings, Fred R. Hirsch, MD, PhD,...
